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Abstract
Background: Abberant aryl hydrocarbon receptor (AhR) expression and AhR pathway activation
are involved in gastric carcinogenesis. However, the relationship between AhR pathway activation
and gastric cancer progression is still unclear. In present study, we used 2,3,7,8-tetrachlorodibenzo-
para-dioxin (TCDD), a classic and most potent ligand of AhR, to activate AhR pathway and
investigated the effect of AhR pathway activation on human gastric cancer AGS cell invasion and
explored the corresponding mechanism.
Results: To determine whether AhR pathway can be activated in AGS cells, we examined the
expression of CYP1A1, a classic target gene of AhR pathway, following TCDD exposure. RT-PCR
and western blot analysis showed that both CYP1A1 mRNA and protein expression were
increased in a dose-dependent manner following TCDD treatment and AhR antagonist resveratrol
(RSV) could reverse this TCDD-induced CYP1A1 expression. To determine whether TCDD
treatment of AGS cells results in an induction of MMP-9 expression, we detected MMP-9 mRNA
using RT-PCR and detected MMP-9 enzymatic activity using gelatin zymography. The results
showed that both MMP-9 mRNA expression and enzymatic activity were gradually increased with
the concentration increase of TCDD in media and these changes could be reversed by RSV
treatment in a dose-dependent manner. To examine whether AhR activation-induced MMP-9
expression and activity in AGS cells results in increased migration and invasion, we performed
wound healing migration assay and transwell migration and invasion assay. After TCDD treatment,
the migration distance and the migration and invasion abilities of AGS cells were increased with a
dose-dependent manner. To demonstrate AhR activation-induced MMP-9 expression is mediated
by c-Jun, siRNA transfection was performed to silence c-Jun mRNA in AGS cells. The results
showed that MMP-9 mRNA expression and activity in untreated control AGS cells were very weak;
After TCDD (10 nmol/L) treatment, MMP-9 mRNA expression and activity were significant
increased; This TCDD-induced MMP-9 expression and activity increase could be abolished by c-Jun
siRNA transfection.
Conclusion: AhR pathway activation enhances gastric cancer cell invasiveness likely through a c-
Jun-dependent induction of MMP-9. Our results provide insight into the mechanism and function
of the AhR pathway and its impact on gastric cancer progression.
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Background
Aryl hydrocarbon receptor (AhR) is a ligand-activated
transcription factor of the basic helix-loop-helix/Per-Arnt-
Sim family. In the absence of ligand, AhR is present in the
cytosol in the form of a complex with two chaperone
Hsp90s, a smal protein (p23), and an immunophilin-like
protein (XAP2) [1,2]. Upon ligand such as 2,3,7,8-tetra-
chlorodibenzo-para-dioxin (TCDD, the most potent and
classical exogenous AhR ligand) binding, the chaperon
proteins dissociate and AhR translocate into the nucleus
to form a heterodimer with its partner molecule aryl
hydrocarbon receptor nuclear translocator (ARNT) [3,4].
This heterodimer binds to the specific DNA region termed
dioxin response element (DRE), which has a core
sequence of 5'-TNGCGTG-3', and thereby activates a bat-
tery of genes expression [5-7].
Historically, studies of AhR pathway have focused on the
transcriptional regulation of genes encoding xenobiotic
metabolizing enzymes such as cytochrome P450 enzymes
[8]. Recent studies demonstrated a close relationship
between AhR and mammary gland tumorigenesis [7,9].
AhR gene polymorphisms have been linked to an
increased risk of lung and breast cancers [10,11].
Increased expression of AhR has been reported in lung,
breast, and pancreatic cancers in humans [7,12,13]. Stud-
ies also suggest that constitutively active AhR may pro-
mote hepatocarcinogenesis in mice [14]. These data
indicated a close relationship between AhR and tumori-
genesis. However, the relationship between AhR and
tumor progression is not clear.
Tumor cells invasion and metastasis is a complicated
process among which degradation of extracellular matrix
(ECM) and basement membrane is a crucial step. Tumor
invasion and metastasis relies on the expression of matrix
metalloproteinases (MMPs) to destroy the ECM and base-
ment membrane to allow cell migration. MMPs are a
group of zinc dependent metallopeptidases [15-17].
Matrix metalloproteinase-9 (MMP-9) is one of the type IV
collagenase/gelatinases, which degrade basement mem-
brane collagens and gelatins [16]. MMP-9 is widely asso-
ciated with tumor invasion and metastasis [17]. The
synthesis of MMP-9 is regulated by several growth factors,
cytokines and hormones [16,18]. Recent study linked
TCDD-associated lesions with aberrant matrix metabo-
lism [8]. Microarray data demonstrate that TCDD/AhR
alter expression of genes involve in matrix metabolism
and deposition [8]. Villano et al [19] and Haque et al [18]
reported that AhR agonist TCDD could induce MMP-9
expression in huamn melanoma cells and prostate cancer
cells. These studies suggest that the MMP-9 expression
may be a common endpoint for activation of the AhR
pathway [8,19].
Gastric cancer is the fourth most common malignancy
and the second most frequent cause of cancer-related
death in the world [20]. Gastric cancer cells invasion and
metastasis often lead to a poor prognosis. Several studies
linked AhR pathway activation to gastric carcinogenesis.
Chen et al found increased expression of AhR in two
human gastric cancer cell lines (RF1 and RF48) by micro-
array analysis [21]. Ma et al reported that concurrent
expression of AhR and CYP1A1 is correlated with gastric
cancer development [22]. Andersson et al found that con-
stitutively activated AhR could induce stomach tumors in
a transgenic mouse model [23]. In another of our studies,
we found that AhR expression and nuclear translocation
were significant higher in gastric cancer than in premalig-
nant lesions and normal gastric mucosa [24]. However,
the relationship between AhR pathway activation and gas-
tric cancer invasion and metastasis is still not clear. There-
fore, we investigated the effect of AhR pathway activation
on human gastric cancer cells. Our data presented here
demonstrate that AhR pathway can be activated in gastric
cancer AGS cells and AhR pathway activation in AGS cells
induces MMP-9 expression and enhances AGS cells migra-
tion and invasion activity. Furthermore, our data show
that this AhR activation-induced MMP-9 expression is
mediated by c-Jun.
Results and discussion
AhR pathway activation in AGS cells
In another of our studies we have demonstrated that there
was a high level of AhR expression in AGS cells [24]. To
determine whether AhR pathway can be activated in this
cell line, we examined the expression of Cytochrome P-
450 1A1 (CYP1A1), a classic target gene of AhR pathway,
following AhR agonist TCDD exposure. RT-PCR and west-
ern blot analysis showed that both CYP1A1 mRNA (Fig.
1A) and protein (Fig. 1B) expression in AGS cells were
increased in a dose-dependent manner following TCDD
treatment. To determine whether this TCDD-induced
CYP1A1 expression is AhR-dependent, AhR antagonist
resveratrol (RSV) was used to block AhR pathway. As
shown in Fig. 1C and 1D, RSV could reverse TCDD-
induced CYP1A1 expression in a dose-dependent manner.
These data demonstrated that AhR pathway can be acti-
vated in AGS cells by TCDD.
AhR pathway activation in AGS cells induce MMP-9 
expression
Previous studies have shown that in several cancer cells,
AhR agonist TCDD exposure activates MMP-9 gene
expression [18,19]. In order to determine whether TCDD
treatment of AGS cells results in an induction of MMP-9
expression, we detected MMP-9 mRNA using RT-PCR fol-
lowing TCDD exposure. As shown in fig. 2A, MMP-9
mRNA expression was induced in a dose-dependent man-BMC Cell Biology 2009, 10:27 http://www.biomedcentral.com/1471-2121/10/27
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ner following TCDD treatment. To examine the role of the
AhR pathway in mediating TCDD-induced MMP-9
expression in AGS cells, cultures were co-treated with
TCDD and the AhR antagonist resveratrol. Co-treatment
with resveratrol abolished TCDD-induced MMP-9 expres-
sion (fig. 2C) demonstrated that TCDD-activation of
MMP-9 expression is dependent on the AhR pathway.
Above data indicate that AhR pathway activation in AGS
cells induces MMP-9 mRNA expression. In most cell types,
the gene transcription of MMP-9 is inducible, and after
translation the enzyme is immediately secreted and acti-
vated through the cysteine-switch mechanism [25]. To
determine whether these changes in gene expression fol-
lowing AhR pathway activation result in changes in MMP-
9 enzymatic activity, we performed gelatin zymography.
The results showed that MMP-9 activity in media is grad-
ually increased with the concentration increase of TCDD
in media (fig. 2B) and these changes could be reversed by
resveratrol treatment in a dose-dependent manner (fig.
2D). These data demonstrate that AhR pathway activa-
tion-induced increase in MMP-9 expression correlates
with an increase in MMP-9 activity.
AhR pathway activation enhances AGS cells migration and 
invasion
MMP-9 is one of the type IV collagenase/gelatinases that
can degrade ECM components. MMP-9 is widely associ-
ated with tumor invasion and metastasis [17]. Studies
have demonstrated a significant correlation between
MMP-9 expression and invasiveness and lymph node
metastasis of gastric carcinomas [26-28]. To examine
whether AhR activation-induced MMP-9 expression and
activity in AGS cells results in increased migration and
invasion, we performed wound healing migration assay
and transwell migration and invasion assay. After TCDD
treatment, the migration distance of AGS cells was signif-
icantly increased with a dose-dependent manner when
compared with control cells (P < 0.01) (fig. 3A). Transwell
results showed a significant increase of migration (fig. 3B)
and invasion (fig. 3C) abilities of AGS cells when the cells
were incubated with TCDD in concentrations from 0.1
AhR agonist TCDD and AhR antagonist RSV regulated  CYP1A11 expression in AGS cells Figure 1
AhR agonist TCDD and AhR antagonist RSV regu-
lated CYP1A11 expression in AGS cells. After different 
concentrations (as shown above) of TCDD treatment for 24 
hours, (A) RT-PCR analysis of CYP1A1 mRNA expression in 
a concentration-response. (B) Western blot analysis of 
CYP1A1 protein expression in a concentration-response. 
After co-treatment with TCDD (1 nM) and RSV (at different 
concentrations as shown above) for 24 hours, (C) mRNA 
expression of CYP1A1 was detected by RT-PCR. (D) Protein 
expression of CYP1A1 was detected by Western blot.
AhR agonist TCDD and AhR antagonist RSV regulated MMP- 9 expression and activity in AGS cells Figure 2
AhR agonist TCDD and AhR antagonist RSV regu-
lated MMP-9 expression and activity in AGS cells. 
After different concentrations (as shown above) of TCDD 
treatment for 24 hours, (A) RT-PCR analysis of MMP-9 
mRNA expression in a concentration-response. (B) Gelatin 
zymography analysis of MMP-9 protein activity in a concen-
tration-response. After co-treatment with TCDD (1 nM) and 
RSV (at different concentrations as shown above) for 24 
hours, (C) mRNA expression of MMP-9 was detected by RT-
PCR. (D) Protein activity of MMP-9 was detected by gelatin 
zymography.
The effect of AhR agonist TCDD on AGS cells migration and  invasion Figure 3
The effect of AhR agonist TCDD on AGS cells migra-
tion and invasion. (A) Wound healing migration assay. (B) 
Transwell migration assay. (C) Transwell invasion assay.BMC Cell Biology 2009, 10:27 http://www.biomedcentral.com/1471-2121/10/27
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nmol/L (P < 0.01) to 100 nmol/l (p < 0.01). no significant
effect on the migration and invasion was found at TCDD
concentration < 0.1 nmol/l (p > 0.05). These results dem-
onstrated that AhR pathway activation enhances gastric
cancer AGS cells migration and invasion. Degradation of
ECM and basement membrane is an essential step in
tumor invasion and metastasis. It involves the action of
matrix metalloproteinases (MMPs). Our study demon-
strated that AhR pathway activation could induce MMP-9
expression and enzymatic activity, and promote AGS cells
migration and invasion. Other studies indicated that AhR
pathway activation could induce a variety of MMPs
expression [19,29]. AhR pathway activation enhances gas-
tric cancer AGS cells migration and invasion may be also
due to other MMPs expression besides MMP-9 expression.
c-Jun mediated MMP-9 expression induced by AhR 
pathway activation
The mechanism of TCDD-induced changes in MMP-9
expression is not entirely clear. Recent studies reported
that TCDD can induce c-Jun expression [30,31] and c-Jun
is a target gene of AhR pathway [8]; the promoter
sequence in the 5'-flanking region of human MMP-9 gene
contains c-Jun binding sites [16] and c-Jun can induced
MMP-9 expression [32]; the transcription activity of c-Jun
is significant enhanced in gastric cancer [33]. Basing on
these study results, we proposed a hypothesis that TCDD-
induced MMP-9 expression in AGS cells is mediated by c-
Jun. To demonstrate this hypothesis, we first detected the
c-Jun expression in AGS cells following TCDD treatment,
and found that both c-Jun mRNA (fig. 4A and 4C) and
c-Jun mediates TCDD-induced MMP-9 expression and activity Figure 4
c-Jun mediates TCDD-induced MMP-9 expression and activity. (A) TCDD induces c-Jun mRNA expression in a dose-
dependent manner. (B) TCDD induces c-Jun protein expression in a dose-dependent manner. (C) TCDD induces c-Jun mRNA 
expression in a time-dependent manner. (D) TCDD induces c-Jun protein expression in a time-dependent manner. (E) RSV 
reverses TCDD-induced c-Jun mRNA expression. (F) RSV reverses TCDD-induced c-Jun protein expression. (G) c-Jun siRNA 
silences c-Jun mRNA expression. (H) c-Jun siRNA silences c-Jun protein expression. (I) c-Jun siRNA inhibits TCDD-induced 
MMP-9 mRNA expression. (J) c-Jun siRNA inhibits TCDD-induced MMP-9 activity increase.BMC Cell Biology 2009, 10:27 http://www.biomedcentral.com/1471-2121/10/27
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protein (fig. 4B and 4D) expression in AGS cells were
increased in a dose (fig. 4A and 4B) and time (fig. 4C and
4D) dependent manner following TCDD treatment, and
this TCDD-induced c-Jun expression could be reserved by
AhR antagonist resveratrol (fig. 4E and 4F). Above data
demonstrated that c-Jun is a target gene of AhR pathway
in AGS cells. To further demonstrate that c-Jun can medi-
ate TCDD-induced MMP-9 expression, siRNA transfection
was performed to silence c-Jun mRNA in AGS cells. The
results demonstrated that c-Jun siRNA (final concentra-
tion 50 nmol/L) transfection almost completely abol-
ished c-Jun expression in AGS cells both in mRNA level
(fig. 4G) and in protein level (fig. 4H). Therefore, after c-
Jun siRNA transfection for 48 hours, AGS cells were
treated with TCDD at concentration 10 nmol/L for 24
hours, cell pellet and culture media were collected, and
MMP-9 mRNA expression and activity were measured. As
shown in fig. 4I and 4J, MMP-9 mRNA expression and
activity in untreated control AGS cells were very weak;
After TCDD (10 nmol/L) treatment, MMP-9 mRNA
expression and activity were significant increased; This
TCDD-induced MMP-9 expression and activity increase
could be abolished by c-Jun siRNA transfection and not be
influenced by control siRNA transfection. Above data
demonstrated that c-Jun mediated MMP-9 expression
induced by AhR pathway activation in AGS cells.
Conclusion
In conclusion, the present study demonstrate that AhR
pathway can be activated in gastric cancer AGS cells and
AhR pathway activation induces MMP-9 expression and
activity which ultimately contributes to AGS migration
and invasion in vitro. Furthermore, our data show that
this AhR activation-induced MMP-9 expression is medi-
ated by c-Jun. Because degradation of ECM and basement
membrane is an essential step in tumor invasion and
metastasis, our results provide insight into the mechanism
and function of the AhR pathway and its impact on these
processes during gastric cancer progression.
Methods
Cell culture
Gastric cancer cell line AGS was obtained from the Amer-
ican Type Culture Collection (ATCC, Rockville, MD), and
was maintained in RPMI 1640 medium (Hyclone) sup-
plemented with 2 mM glutamine, 10% fetal bovine serum
(Hyclone), 100 units/ml of penicillin, and 100 μg/ml of
gentamycin. Cellular environment was maintained at 5%
CO2 and 37°C. Cells were harvested from the exponential
growth phase and total RNA and protein were prepared as
described below.
Treatment of cells
TCDD and Resveratrol were purchased from Sigma Chem-
ical Company (Bellefonte, PA, USA). After incubation for
24 hours, the cells were treated with TCDD at different
concentrations (0, 0.01, 0.1, 1, 10, 100 nM) or TCDD (1
nM) plus Resveratrol (0, 1, 5, 10, 20 μM) for 24 hours, or
treated with TCDD (1 nM) for different time (0, 1, 6, 24,
48, 72 hours) respectively. All drugs were dissolved in
dimethyl sulphoxide (DMSO). Control cells received
0.1% DMSO only.
Small interfering RNA synthesis
Small interfering RNAs (siRNAs) were synthesized and
high-performance purified (Ribo Biotechnology,
Guangzhou). c-Jun siRNAs (sense, CCAAGAACGUGACA-
GAUGA-dTdT; antisense, UCAUCUGUCACGUUCU-
UGG-dTdT) and control siRNAs (sense, AG GAG AUA UU
UCGAGGCUU-dTdT; antisense, AAGCUCGAA AUA UC
UCCU-dTdT), bearing no homology with any known
human genes, were dissolved in RNase-free ddH2O to a
final concentration of 20 μmol/L.
Small interfering RNA transfection
Cells (5 × 105) were plated onto wells of six-well cell cul-
ture plates and allowed to adhere for 24 hours. Four
microliters Lipofectamine2000 (Invitrogen) per well were
added to serum-free Opti MEM (Invitrogen) for a final
complexing volume of 250 μl, gently mixed, and incu-
bated at room temperature for 5 minutes. Five microliters
of siRNA solution per well were diluted with 250 μl
serum-free Opti MEM. Mix the diluted siRNA solution
and the diluted Lipofectamine2000 gently, and incubate
at room temperature for 30 minutes. The
Lipofectamine2000/siRNA complex was added into the
wells containing 1500 μl RPMI 1640 with 10% FBS and
incubated in normal cell culture conditions. All of the
assays were performed after 48 hours.
RNA isolation and RT-PCR
Total RNA of cells was extracted using the Quiagen RNe-
asy Mini Kit (Quiagen) according to the manufacturer's
instructions. cDNA was synthesized with 1 μg total RNA
using reverse transcriptase, ReverTra AceTM (Toyobo Co,
Osaka, Japan) under following condition: 30°C for 10
min, 42°C for 20 min, 99°C for 5 min, and 4°C for 5
min. PCR of cDNA was carried out in a reaction mixture
(30 μl) containing 2 μl of template cDNA, 2.5 mM MgCl2,
200 μM dNTPs, 0.3 μM primer 1 and 2, and 1 unit of Taq
DNA polymerase (New England Biolabs). Amplification
was performed using the following condition: 94°C for 5
min, followed by 25–32 cycles (denature for 45 s at 94°C,
anneal for 30 s, and extend for 30 s at 72°C), and then
72°C for 7 min. The details of primers, annealing temper-
ature, amplification cycles, and PCR product size for each
gene are listed in Table 1. The PCR products were electro-
phoresed on 1.5% agarose gel, stained with ethidium bro-
mide, and visualized with an ultra-violet (UV)
transilluminator. Band intensities in RT-PCR were quanti-BMC Cell Biology 2009, 10:27 http://www.biomedcentral.com/1471-2121/10/27
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fied using Quantity One imaging analysis software. Band
intensities of CYP 1A1, MMP-9 and c-Jun mRNA were nor-
malized with corresponding band intensities of beta-
actin. Data was reported as mean ± SD.
Western blot analysis
Cell pellets were homogenized in a lysis buffer containing
20 mM Hepes, 1 mM EGTA, 50 mM β-glycerophosphate,
2 mM Sodium orthovanadate, 10% Glycerol, 1% Triton
X-100, 1 mM DTT, and 1× Protease Inhibitor Cocktail
(Roche, Mannheim, Germany). Lysate was centrifuged at
13000 rpm and 4 oC for 10 minutes. The supernatant was
the total cell lysate. Protein concentration was measured
using the BCA protein assay kit (Pierce Chemical Co.,
Rockford, IL). Thirty micrograms of protein was loaded
per lane, separated by 10% SDS-polyacrylamide gel elec-
trophoresis, and transferred onto equilibrated polyvinyli-
dene difluoride membrane by electroblotting.
Membranes were blocked with TBS-T buffer containing
5% (w/v) nonfat dry milk. AhR, CYP1A1, c-Jun and beta-
actin were detected for 2 hours using antibodies against
AhR (SC-5579, Santa Cruz Biotechnology, working dilu-
tion 1:150), CYP 1A1 (AB1258, Chemicon International,
working dilution 1: 500), c-Jun (SC-1694, Santa Cruz Bio-
technology, working dilution 1:200) and beta-actin
(#4970, Cell Signaling Technology, working dilution 1:
1000). After secondary antibody incubation (working
dilution 1: 2000), enhanced chemiluminescence (Pierce
Biotechnology, Inc.) was determined by exposure to x-ray
film. Band intensities in Western blot were quantified
using Quantity One imaging analysis software. Band
intensities of CYP 1A1 and c-Jun were normalized with
corresponding band intensities of beta-actin. Data was
reported as mean ± SD.
Gelatin zymography
Media from TCDD treated cultures was electrophoresed
on SDS-PAGE where the gel contains 0.1% (w/v) gelatin.
The gel was incubated overnight in a Zn2+ and Ca2+ con-
taining buffer to allow the MMPs to regain their proper
structure and degrade the gelatin in the gel. Clear white
bands on the Coomassie stained gel are indicative of MMP
activity. Band intensities were quantified using Quantity
One imaging analysis software.
Wound healing migration assay
For the measurement of cell migration during wound
healing, AGS cells were seeded in individual wells of a 6-
well culture plate. When the cells reached a confluent
state, cell layers were wounded with a plastic micropipette
tip having a large orifice. The medium and debris were
aspirated away and replaced by 2.5 ml of fresh serum-free
medium which contained different concentrations of
TCDD (0, 0.01, 0.1, 1, 10, 100 nM). Cells were photo-
graphed every 12 h after wounding by phase contrast
microscopy. For evaluation of "wound closure," five ran-
domly selected points along each wound were marked,
and the horizontal distance of migrating cells from the
initial wound was measured. Data was reported as mean
± SD.
Transwell migration and invasion assay
Treated or untreated control cells were seeded in triplicate
into the upper chamber of a Transwell insert (Corning,
New York, NY, USA) in serum-free medium at a density of
1 × 105 per well. For migration assays, medium containing
5% serum was placed in the lower chamber to act as a che-
moattractant, and cells were further incubated for 18 h.
Nonmigratory cells were removed from the upper cham-
ber by scraping, and the cells remaining on the lower sur-
face of the insert were stained using 0.1% crystal violet for
15 minutes. Cells were counted under a microscope. Inva-
sion assays were done as for the migration assays
described above, except inserts were precoated with the
extracellular matrix (ECM) substitute Matrigel (BD Bio-
sciences) and incubated over a 24-h period. Each clone
was plated in triplicate in each experiment and each exper-
iment was repeated at least thrice. Cell migration (or inva-
sion) ability = (the cell number of treated group/the cell
number of control group) × 100%.
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